Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

BACKGROUND: The phase III KEYNOTE-604 study confirmed the benefit of pembrolizumab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Taken into account the clinical benefits of pembrolizumab and its high cost, this study aimed to assess the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Tan, Chongqing, Yi, Lidan, Wan, Xiaomin, Peng, Liubao, Li, Jianhe, Luo, Xia, Zeng, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592441/
https://www.ncbi.nlm.nih.gov/pubmed/34780478
http://dx.doi.org/10.1371/journal.pone.0258605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592441/
https://www.ncbi.nlm.nih.gov/pubmed/34780478
http://dx.doi.org/10.1371/journal.pone.0258605

Ejemplares similares